Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North…
$LQDA ... Liquidia Technologies assumed with Buy and $76 price target at H.C. Wainwright (58.12) Analyst Matthew Caufield said, "Main reasons we like Liquidia's next YUTREPIA chapter following UTHR settlement. (1) We highlight that the October 2026 settlement with United…
$LQDA upgraded to Strong Buy $77 price tgt at RAYMOND JAMES
@jollie20015 @monaco_biotech $LQDA ... I was just playin...its all good...
@jollie20015 @monaco_biotech $LQDA ... listening to the call... SSSHHH??? ... https://t.co/7PO5d9070c
@monaco_biotech $LQDA ... I hear ya! .. we have seen some wild swings with earnings reports recently... I am not listening to the call... but the management team must be setting things straight as it is at $49 now...
@monaco_biotech $LQDA ... Yo Monaco ... that sucker was down big... and reversed higher ... 70,000 shares traded.... https://t.co/mfnp3znoMh
8 analysts rate LQDA Buy on consensus.
Consensus price target: $60.75 (+5.82% upside from $57.41)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Boyle Dana Chief Accounting Officer | Oct 26, 2026 | Sale | 1,581 | $68.28K |
| Adair Jason Chief Business Officer | Oct 26, 2026 | Sale | 688 | $29.71K |
| Bloch Stephen M director | Oct 5, 2026 | Sale | 235,477 | $6.39M |
| Krepp Sarah Chief Human Resource Officer | Sep 1, 2026 | Sale | 274 | $18.57K |
| Rielly-Gauvin Katherine director | Aug 20, 2026 | Sale | 18,393 | $1.33M |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $158.32M | +1031.18% | $-68.92M |
| 2024 | $14M | -19.97% | $-130.39M |
| 2023 | $17.49M | +9.75% | $-78.5M |
Stock data for LQDA: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics